OverviewSuggest Edit

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical-stage programs in GI disorders and dyslipidemia. The Company discovers, develops and commercializes a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

TypePublic
HQCambridge, US
Websiteironwoodpharma.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)515(-29%)
Job Openings15
Revenue (FY, 2018)$346.6 M(+17%)
Share Price (Jun 2019)$11.2 (+2%)

Key People/Management at Ironwood Pharmaceuticals

Mark Mallon

Mark Mallon

Executive Senior Advisor
Gina Consylman

Gina Consylman

Senior Vice President, Chief Financial Officer
Halley Gilbert

Halley Gilbert

Chief Administrative Officer, SVP
Michael Shetzline

Michael Shetzline

Chief Medical Officer, Senior Vice President and Head of Drug Development
Thomas McCourt

Thomas McCourt

President
Show more

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St
Show all (1)

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Revenue

Ironwood Pharmaceuticals's revenue was reported to be $346.64 m in FY, 2018
USD

Revenue (Q2, 2019)

102.2m

Net income (Q2, 2019)

12.3m

EBIT (Q2, 2019)

21.6m

Market capitalization (10-Jun-2019)

1.7b

Closing stock price (10-Jun-2019)

11.2

Cash (30-Jun-2019)

98.9m
Ironwood Pharmaceuticals's current market capitalization is $1.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

22.9m76.4m149.6m274.0m298.3m346.6m

Revenue growth, %

234%96%83%

Cost of goods sold

12.0k

Gross profit

149.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

52.2m65.1m86.8m69.2m81.1m65.7m68.7m102.2m

Cost of goods sold

2.0m1.9m10.5m12.0k8.2m

General and administrative expense

30.3m29.9m29.3m28.5m30.3m33.0m30.4m36.2m36.9m45.0m55.6m57.8m61.8m61.9m68.4m55.2m64.7m43.2m

R&D expense

23.0m27.1m22.1m25.1m26.6m28.6m25.8m31.8m31.7m37.5m33.7m37.3m37.1m36.5m38.9m46.8m54.0m28.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

75.5m74.3m261.3m54.0m125.7m173.2m

Accounts Receivable

513.0k10.0k2.9m933.0k3.2m21.0m

Inventories

22.1m10.6m6.3m1.1m735.0k

Current Assets

229.1m289.7m500.2m380.2m311.6m266.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

144.5m205.1m95.4m51.3m63.7m256.5m248.1m280.9m277.3m182.9m133.3m182.1m162.6m144.8m145.4m141.6m119.0m98.9m

Accounts Receivable

125.0k13.0k380.0k862.0k1.1m2.6m908.0k1.3m1.2m1.2m4.0m4.3m5.0m6.7m10.2m3.3m22.6m

Inventories

20.6m23.4m13.0m13.0m5.0m1.5m1.1m479.0k1.7m1.1m76.0k593.0k1.7m

Current Assets

275.8m371.3m325.8m304.1m263.9m527.0m505.8m495.7m386.1m382.8m357.9m341.5m314.1m275.7m279.5m248.5m201.8m221.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(272.8m)(189.6m)(142.7m)(81.7m)(116.9m)(282.4m)

Depreciation and Amortization

11.7m12.3m11.6m10.3m8.4m6.1m

Inventories

(11.9m)(3.9m)2.6m(3.1m)346.0k

Accounts Payable

(11.7m)1.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(61.8m)(49.6m)(110.0m)(152.0m)(33.2m)(81.2m)(128.6m)(13.3m)(35.0m)(68.2m)(52.5m)(96.7m)(129.0m)(43.1m)(92.5m)(266.9m)(59.3m)(47.0m)

Depreciation and Amortization

3.1m6.2m9.4m6.0m8.8m2.8m5.3m7.5m2.9m4.8m6.6m1.8m3.5m4.8m1.2m1.5m

Inventories

(1.3m)272.0k224.0k5.0m4.0k71.0k1.1m1.1m(768.0k)

Accounts Payable

(8.0m)(7.7m)2.8m
USDY, 2019

Financial Leverage

-1.4 x
Show all financial metrics

Ironwood Pharmaceuticals Online and Social Media Presence

Embed Graph

Ironwood Pharmaceuticals News and Updates

Ironwood Pharmaceuticals Blogs

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

– “When-issued” trading of CYCN expected to begin on Nasdaq on March 18, 2019 – – Separation completion expected April 1, 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2019-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami .

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 39 th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston .

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

– Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2019-- Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York .

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

– Grew 2018 revenue 16% year-over-year to $347 million , driven primarily by U.S. LINZESS ® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected
Show more

Ironwood Pharmaceuticals Frequently Asked Questions

  • Who are Ironwood Pharmaceuticals key executives?

    Ironwood Pharmaceuticals's key executives are Mark Mallon, Gina Consylman and Halley Gilbert.

  • How many employees does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 515 employees.

  • What is Ironwood Pharmaceuticals revenue?

    Latest Ironwood Pharmaceuticals annual revenue is $346.6 m.

  • What is Ironwood Pharmaceuticals revenue per employee?

    Latest Ironwood Pharmaceuticals revenue per employee is $673.1 k.

  • Who are Ironwood Pharmaceuticals competitors?

    Competitors of Ironwood Pharmaceuticals include Biogen, Inovio Pharmaceuticals and Marinus Pharmaceuticals.

  • Where is Ironwood Pharmaceuticals headquarters?

    Ironwood Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Ironwood Pharmaceuticals offices?

    Ironwood Pharmaceuticals has an office in Cambridge.

  • How many offices does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 1 office.